Antimicrobial Resistance Profile and Longitudinal Trends of Morganella morganii Clinical Isolates in a University Hospital.

Authors

Elif Seren Tanriverdi, Yusuf Yakupogullari, Irem Yildiz, Baris Otlu

Published in

Sisli Etfal Hastanesi tip bulteni. Volume 60. Issue 2. Pages 231-236. Epub Jun 29, 2026.

Abstract

Morganella morganii is an opportunistic Gram-negative pathogen increasingly associated with healthcare-associated infections and antimicrobial resistance. However, long-term epidemiological data from Türkiye remain scarce.
This retrospective study analyzed M. morganii isolates obtained between January 2015 and December 2024 at a 1500-bed tertiary care hospital. Demographic data, clinical specimen sources, and antimicrobial susceptibility results were retrieved from the laboratory database. Identification was performed using conventional methods and MALDI-TOF MS, while antimicrobial susceptibility was determined according to EUCAST guidelines. Linear regression analysis was applied to evaluate resistance trends over time.
A total of 673 non-duplicate isolates were included, predominantly from urine (68.6%), followed by wound (19.2%), blood (4.7%), respiratory (3.6%), abscess (1.9%), and sterile body fluid (1.0%) specimens. The annual incidence ranged from 0.47% in 2015 to 1.9% in 2024, with a transient decline during 2020-2022, likely related to the COVID-19 pandemic. Male patients accounted for 63% of isolates, with a median age of 52 years. Meropenem and amikacin showed the highest overall activity (>98% susceptibility), while cefoxitin demonstrated the lowest efficacy (≈50%). Trend analysis revealed statistically significant increases in resistance to amikacin, imipenem, meropenem, ertapenem, ceftriaxone, ceftazidime, cefoxitin, cefepime, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and ciprofloxacin (all p<0.05), whereas gentamicin showed no significant change. Notably, carbapenem and aminoglycoside resistance increased markedly after 2022.
This study highlights the rising clinical importance of M. morganii, with increasing resistance across multiple antibiotic classes, including carbapenems. The findings underscore the need for continuous surveillance, prudent antimicrobial use, and further genomic studies to elucidate resistance mechanisms and guide effective therapy.

PMID:
42428702
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.